E. Antonio Chiocca

Active 1988–2026

Also published as
E Antonio Chiocca
200
Papers
29,303
Citations
97
h-index
190
i10-index

Citations

Citations per year for E. Antonio Chiocca1980: 1 citations1986: 1 citations1989: 5 citations1990: 6 citations1991: 8 citations1992: 13 citations1993: 10 citations1994: 16 citations1995: 28 citations1996: 15 citations1997: 27 citations1998: 33 citations1999: 61 citations2000: 109 citations2001: 107 citations2002: 124 citations2003: 116 citations2004: 103 citations2005: 144 citations2006: 153 citations2007: 147 citations2008: 177 citations2009: 193 citations2010: 176 citations2011: 200 citations2012: 241 citations2013: 227 citations2014: 202 citations2015: 206 citations2016: 189 citations2017: 220 citations2018: 237 citations2019: 819 citations2020: 1,203 citations2021: 1,328 citations2022: 1,216 citations2023: 1,055 citations2024: 1,521 citations2025: 871 citations2026: 41 citations1981–1985: no citations, so these years are not shown1987–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,822 citing papers, 29.6% of this breakdownChina: 2,216 citing papers, 17.1% of this breakdownGermany: 710 citing papers, 5.5% of this breakdownUnited Kingdom: 613 citing papers, 4.7% of this breakdownItaly: 462 citing papers, 3.6% of this breakdownCanada: 414 citing papers, 3.2% of this breakdownFrance: 366 citing papers, 2.8% of this breakdownNetherlands: 281 citing papers, 2.2% of this breakdownAustralia: 265 citing papers, 2.1% of this breakdownSouth Korea: 265 citing papers, 2% of this breakdownSwitzerland: 264 citing papers, 2% of this breakdownJapan: 256 citing papers, 2% of this breakdown
0%29.6%Other 23.2%

Fields

  • Biochemistry, Genetics and Molecular Biology44.5%
  • Medicine33%
  • Immunology and Microbiology10.4%
  • Engineering2.9%
  • Neuroscience2.8%
  • Materials Science2.7%
  • Other3.7%

Topics

  • Glioma Diagnosis and Treatment6.3%
  • Virus-based gene therapy research5.1%
  • CAR-T cell therapy research5%
  • MicroRNA in disease regulation4.8%
  • Immunotherapy and Immune Responses4%
  • Extracellular vesicles in disease3.9%
  • Other70.9%

Coauthors

All papers

Open in search
  1. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Taphoorn, Joerg-Christian Tonn, Jonathan Tsang, Roel G.W. Verhaak, Andreas von Deimling, Wolfgang Wick, Gelareh Zadeh, David A. Reardon, Kenneth Aldape, Martin J. van den Bent - Neuro-Oncology 2020 cited by 1,137

  2. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heather Daley, Patrick Y. Wen, E. Antonio Chiocca, Maegan Harden, Niall J. Lennon, Stacey Gabriel, Gad Getz, Eric S. Lander, Aviv Regev, Jerome Ritz, Donna Neuberg, Scott J. Rodig, Keith L. Ligon, Mario L. Suvà, Kai W. Wucherpfennig, Nir Hacohen, Edward F. Fritsch, Kenneth J. Livak, Patrick A. Ott, Catherine J. Wu, David A. Reardon - Nature 2018 cited by 1,464

  3. The emerging field of oncolytic virus-based cancer immunotherapy

    Authors: , , , , - Trends in cancer 2022 cited by 288

  4. Clinical trial links oncolytic immunoactivation to survival in glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott J. Rodig, Patrick Y. Wen, Eudocia Q. Lee, Lakshmi Nayak, Ugonma Chukwueke, L. Nicolas Gonzalez Castro, Sydney Dumont, Tracy T. Batchelor, Kara A. Kittelberger, Ekaterina Tikhonova, Natalia Miheecheva, D Tabakov, Nara Shin, Alisa M. Gorbacheva, Artemy Shumskiy, Felix Frenkel, Estuardo Aguilar-Córdova, Laura K. Aguilar, David Krisky, James Wechuck, Andrea G. Manzanera, Christopher Matheny, Paul P. Tak, Francesca Barone, Daniel Kovarsky, Itay Tirosh, Mario L. Suvà, Kai W. Wucherpfennig, Keith L. Ligon, David A. Reardon, E. Antonio Chiocca - Nature 2023 cited by 256

  5. Mechanisms and therapeutic implications of hypermutation in gliomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maïté Verreault, Marine Giry, Erell Guillerm, Samy Ammari, Frédéric Beuvon, Karima Mokhtari, Agustí Alentorn, Caroline Dehais, Caroline Houillier, Florence Laigle–Donadey, Dimitri Psimaras, Eudocia Q. Lee, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Alexandre Carpentier, Philippe Cornu, Laurent Capelle, Bertrand Mathon, Jill S. Barnholtz‐Sloan, Arnab Chakravarti, Wenya Linda Bi, E. Antonio Chiocca, Katie Fehnel, Sanda Alexandrescu, N. Susan, Daphne A. Haas‐Kogan, Tracy T. Batchelor, Garrett M. Frampton, Brian M. Alexander, Raymond Y. Huang, Azra H. Ligon, Florence Coulet, Jean‐Yves Delattre, Khê Hoang‐Xuan, David M. Meredith, Sandro Santagata, Alex Duval, Marc Sanson, Andrew D. Cherniack, Patrick Y. Wen, David A. Reardon, Aurélien Marabelle, Peter J. Park, Ahmed Idbaïh, Rameen Beroukhim, Pratiti Bandopadhayay, Franck Bielle, Keith L. Ligon - Nature 2020 cited by 720

  6. Advances in local therapy for glioblastoma — taking the fight to the tumour

    Authors: , , , - Nature Reviews Neurology 2022 cited by 347

  7. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science Advances 2018 cited by 610

  8. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew P. Frosch, David N. Louis, Gordon J. Freeman, Keith L. Ligon, Alexander Marson, E. Antonio Chiocca, David A. Reardon, Aviv Regev, Mario L. Suvà, Kai W. Wucherpfennig - Cell 2021 cited by 412

  9. STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models

    Authors: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2022 cited by 167

  10. Oncolytic Viruses in Cancer Treatment

    Authors: , , , - JAMA Oncology 2016 cited by 580

  11. Glial and myeloid heterogeneity in the brain tumour microenvironment

    Authors: , , , , , - Nature reviews. Cancer 2021 cited by 210

  12. Multiplexed Profiling of Single Extracellular Vesicles

    Authors: , , , , , , , , , - ACS Nano 2017 cited by 372

  13. Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents

    Authors: , , , , , , , , - Nature Communications 2017 cited by 333

  14. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates

    Authors: , , , , , , , , , , , , , , - Nature Biomedical Engineering 2022 cited by 114

  15. Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles

    Authors: , , , , , , , , - ACS Nano 2022 cited by 130

  16. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2019 cited by 266

  17. Oncolytic Viruses and Their Application to Cancer Immunotherapy

    Authors: , - Cancer Immunology Research 2014 cited by 396

  18. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

    Authors: , , , , , , , , , , , , , , , - Oncotarget 2016 cited by 239

  19. Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity

    Authors: , , , , , , , , , , , , - Nature Cancer 2022 cited by 79

  20. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2021 cited by 110

  21. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma

    Authors: , , , , , , , , , , , , - Nature Communications 2021 cited by 111

  22. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 172

  23. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

    Authors: , , , , , , , , , , , , , , , , , - Scientific Reports 2015 cited by 333

  24. Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Extracellular Vesicles 2019 cited by 132